Fondaparinux sodium
Products billed under this code include Arixtra, Fondaparinux Sodium.
Payment limit per 0.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Arixtra, Fondaparinux Sodium.
Payment limit per 0.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Arixtra | Mylan Institutional LLC | 67457-0592-10 | 50 | $39.90 |
| Arixtra | Mylan Institutional LLC | 67457-0593-04 | 100 | $79.80 |
| Arixtra | Mylan Institutional LLC | 67457-0594-06 | 150 | $119.70 |
| Arixtra | Mylan Institutional LLC | 67457-0595-08 | 200 | $159.60 |
| Fondaparinux Sodium | Sandoz Inc. | 00781-3443-95 | 50 | $39.90 |
| Fondaparinux Sodium | Sandoz Inc. | 00781-3454-95 | 100 | $79.80 |
| Fondaparinux Sodium | Sandoz Inc. | 00781-3465-95 | 150 | $119.70 |
| Fondaparinux Sodium | Sandoz Inc. | 00781-3476-95 | 200 | $159.60 |
| Fondaparinux Sodium | Dr. Reddy's Laboratories Inc. | 55111-0678-02 | 10 | $7.98 |
| Fondaparinux Sodium | Dr. Reddy's Laboratories Inc. | 55111-0678-10 | 50 | $39.90 |
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Fondaparinux Sodium | Dr. Reddy's Laboratories Inc. | 55111-0679-02 | 20 | $15.96 |
| Fondaparinux Sodium | Dr. Reddy's Laboratories Inc. | 55111-0679-10 | 100 | $79.80 |
| Fondaparinux Sodium | Dr. Reddy's Laboratories Inc. | 55111-0680-02 | 30 | $23.94 |
| Fondaparinux Sodium | Dr. Reddy's Laboratories Inc. | 55111-0680-10 | 150 | $119.70 |
| Fondaparinux Sodium | Dr. Reddy's Laboratories Inc. | 55111-0681-02 | 40 | $31.92 |
| Fondaparinux Sodium | Dr. Reddy's Laboratories Inc. | 55111-0681-10 | 200 | $159.60 |
| Fondaparinux Sodium | Eugia US LLC | 55150-0230-10 | 50 | $39.90 |
| Fondaparinux Sodium | Eugia US LLC | 55150-0231-10 | 100 | $79.80 |
| Fondaparinux Sodium | Eugia US LLC | 55150-0232-10 | 150 | $119.70 |
| Fondaparinux Sodium | Eugia US LLC | 55150-0233-10 | 200 | $159.60 |
| Fondaparinux Sodium | Mylan Institutional LLC | 67457-0582-10 | 50 | $39.90 |
| Fondaparinux Sodium | Mylan Institutional LLC | 67457-0583-04 | 100 | $79.80 |
| Fondaparinux Sodium | Mylan Institutional LLC | 67457-0584-06 | 150 | $119.70 |
| Fondaparinux Sodium | Mylan Institutional LLC | 67457-0585-08 | 200 | $159.60 |
| Fondaparinux Sodium | Zydus Pharmaceuticals (USA) Inc. | 70710-1514-06 | 50 | $39.90 |
| Fondaparinux Sodium | Zydus Pharmaceuticals (USA) Inc. | 70710-1514-09 | 10 | $7.98 |
| Fondaparinux Sodium | Zydus Pharmaceuticals (USA) Inc. | 70710-1515-06 | 100 | $79.80 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $0.798 | −$0.127 | 0.5 MG | Fondaparinux sodium | v1, posted September 17, 2026 |
| 3Q26 | $0.925 | +$0.128 | 0.5 MG | Fondaparinux sodium | v1, posted September 15, 2026 |
| 2Q26 | $0.797 | −$0.08 | 0.5 MG | Fondaparinux sodium | v1, posted September 15, 2026 |
| 1Q26 | $0.877 | +$0.154 | 0.5 MG | Fondaparinux sodium | v1, posted September 15, 2026 |
| 4Q25 | $0.723 | +$0.004 | 0.5 MG | Fondaparinux sodium | v1, posted September 8, 2026 |
| 3Q25 | $0.719 | −$0.136 | 0.5 MG | Fondaparinux sodium | v1, posted March 10, 2026 |
| 2Q25 | $0.855 | +$0.183 | 0.5 MG | Fondaparinux sodium | v1, posted March 10, 2026 |
| 1Q25 | $0.672 | −$0.248 | 0.5 MG | Fondaparinux sodium | v1, posted December 19, 2025 |
| 4Q24 | $0.92 | −$0.161 | 0.5 MG | Fondaparinux sodium | v1, posted June 11, 2025 |
| 3Q24 | $1.081 | +$0.05 | 0.5 MG | Fondaparinux sodium | v1, posted June 11, 2025 |
| 2Q24 | $1.031 | −$0.062 | 0.5 MG | Fondaparinux sodium | v1, posted March 11, 2025 |
| 1Q24 | $1.093 | +$0.074 | 0.5 MG | Fondaparinux sodium | v1, posted December 19, 2024 |
| 4Q23 | $1.019 | −$0.052 | 0.5 MG | Fondaparinux sodium | v1, posted October 10, 2024 |
| 3Q23 | $1.071 | +$0.001 | 0.5 MG | Fondaparinux sodium | v1, posted June 5, 2024 |
| 2Q23 | $1.07 | +$0.069 | 0.5 MG | Fondaparinux sodium | v1, posted February 23, 2024 |
| 1Q23 | $1.001 | −$0.215 | 0.5 MG | Fondaparinux sodium | v1, posted December 6, 2023 |
| 4Q22 | $1.216 | +$0.06 | 0.5 MG | Fondaparinux sodium | v1, posted June 22, 2023 |
| 3Q22 | $1.156 | −$0.088 | 0.5 MG | Fondaparinux sodium | v1, posted June 9, 2023 |
| 2Q22 | $1.244 | −$0.221 | 0.5 MG | Fondaparinux sodium | v1, posted December 14, 2022 |
| 1Q22 | $1.465 | +$0.037 | 0.5 MG | Fondaparinux sodium | v1, posted June 8, 2022 |
| 4Q21 | $1.428 | −$0.213 | 0.5 MG | Fondaparinux sodium | v1, posted June 2, 2022 |
| 3Q21 | $1.641 | −$0.405 | 0.5 MG | Fondaparinux sodium | v1, posted June 2, 2022 |
| 2Q21 | $2.046 | +$0.338 | 0.5 MG | Fondaparinux sodium | v1, posted March 1, 2022 |
| 1Q21 | $1.708 | – | 0.5 MG | Fondaparinux sodium | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.